Bioxytran (BIXT) Notes Payables (2012 - 2026)
Bioxytran (BIXT) posted Notes Payables of $476489.0 for Q1 2026, up 18.13% sequentially from $403353.0 in Q4 2025, and down 40.81% YoY from $805000.0 in Q1 2025.
Bioxytran (BIXT) Notes Payables (2012 - 2026) Analysis & Trends
Bioxytran has reported Notes Payables for 15 years, with the latest figure at $476489.0 in Q1 2026.
- Quarterly Notes Payables fell 40.81% year-over-year to $476489.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $476489.0 (down 40.81% YoY) and the FY2025 annual result came in at $403353.0, up 740.32% from the prior year.
- Notes Payables advanced to $476489.0 in Q1 2026 per BIXT's latest filing, from $403353.0 in the prior quarter.
- Over five years, Notes Payables peaked at $3.6 million in Q2 2022 and troughed at $48000.0 in Q4 2024.
- A 5-year average of $1.2 million and a median of $805000.0 in 2025 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2024 and 2025: Notes Payables plunged 97.47% in 2024, then surged 740.32% in 2025.
- Over 5 years, Notes Payables stood at $2.2 million in 2022, then declined by 12.24% to $1.9 million in 2023, then slumped by 97.47% to $48000.0 in 2024, then soared by 740.32% to $403353.0 in 2025, then rose by 18.13% to $476489.0 in 2026.
- According to Business Quant data, Notes Payables over the past three periods registered $476489.0, $403353.0, and $50000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 476,489.00 |
| Dec 31, 2025 | 403,353.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 684,002.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 48,000.00 |
| Sep 30, 2024 | 140,588.00 |
| Jun 30, 2024 | 730,000.00 |
| Mar 31, 2024 | 861,500.00 |
| Dec 31, 2023 | 1.90 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.17 Mn |
| Dec 31, 2022 | 2.17 Mn |
| Sep 30, 2022 | 2.16 Mn |
| Jun 30, 2022 | 3.59 Mn |
| Mar 31, 2022 | 796,506.00 |
| Dec 31, 2021 | 2.12 Mn |
| Sep 30, 2021 | 338,826.00 |
| Jun 30, 2021 | 1.06 Mn |